Silo recently extended Columbia University agreement to continue research for novel therapeutics to treat Alzheimer’s disease and stress-induced anxiety disorder Preclinical studies demonstrate Silo’s jointly-developed Z-pod(TM) delivery technology holds and distributes therapeutics in a time-released manner to potentially provide targeted delivery Additional treatment research includes funding for the UCSF Translational Psychedelic Program to study effects … Continue reading “Silo Pharma Inc. (NASDAQ: SILO) Extends Columbia University Agreement to Continue Research for Therapeutics to Treat Alzheimer’s Disease”
Delic Holdings (CSE: DELC) (OTCQB: DELCF) (FRA: 6X0), a leader in new medicines and treatments for a modern world, today announced details regarding Delic Labs CSO and President Dr. Markus Roggen’s participation at the MJBizCon in Las Vegas, Nevada, on Nov. 15, 2022. With more than 1,400 exhibitors, 35,000 attendees and countless networking opportunities, MJBizCon … Continue reading “NetworkNewsBreaks – Delic Holdings Corp. (CSE: DELC) (OTCQB: DELCF) (FRA: 6X0) Announces Delic Labs’ Participation at 11th Annual MJBizCon”
Silo Pharma (NASDAQ: SILO) recently uplisted to the NASDAQ after the exciting progress it made over the last year. “Silo Pharma announced that it had successfully priced its fully underwritten initial public offering, raising gross proceeds of $5 million through the sale of one million shares of common stock,” reads a recent article. “Originally founded … Continue reading “NetworkNewsBreaks – Silo Pharma Inc. (NASDAQ: SILO) Distinctive with Ground-Breaking Research, Commitment to Developing Innovative Solutions”
Silo Pharma, Inc recently uplisted to the Nasdaq Capital Market, raising gross proceeds of $5 million The biopharmaceutical company has sought to merge traditional therapeutics and psychedelic research, entering into a series of joint ventures with leading medical universities to carry out research into the field Meanwhile, psychedelics are gaining increasing favour within the United … Continue reading “Silo Pharma Inc. (NASDAQ: SILO) Successfully Uplists, Commences Trading on the Nasdaq Market”
Ketamine Wellness Centers (“KWC”), the largest ketamine therapy provider in the U.S. and a subsidiary of Delic Holdings (CSE: DELC) (OTCQB: DELCF) (FRA: 6X0), has become one of a few U.S.-based ketamine therapy providers to offer Medicare coverage to patients at eight KWC clinics across the country. Under Medicare, KWC is accepting a limited number … Continue reading “NetworkNewsBreaks – Delic Holdings Corp.’s (CSE: DELC) (OTCQB: DELCF) (FRA: 6X0) KWC Expands Insurance Coverage with Medicare for Ketamine Therapy Patients”
Tryp Therapeutics (CSE: TRYP) (OTCQB: TRYPF), a clinical-stage biotechnology company focused on developing psilocybin-based compounds for diseases with unmet medical needs, today announced the filing of two new provisional patent applications. According to the update, one application, #63/405,786, is for the use of psilocybin for the treatment of patients with fibromyalgia and the other, #63/375,305, … Continue reading “NetworkNewsBreaks – Tryp Therapeutics Inc. (CSE: TRYP) (OTCQB: TRYPF) Announces Methodical Expansion of Its IP Portfolio”
Ketamine Wellness Centers (“KWC”), the largest ketamine therapy provider in the U.S. and a subsidiary of Delic Holdings (CSE: DELC) (OTCQB: DELCF) (FRA: 6X0), has expanded its partnership with the Veterans Administration Community Care Network (“VA-CCN”) to cover SPRAVATO(R) treatments at select clinics. VA-CCN patients experiencing treatment-resistant depression with prior authorization from the VA-CCN will … Continue reading “NetworkNewsBreaks – Delic Holdings Corp.’s (CSE: DELC) (OTCQB: DELCF) (FRA: 6X0) KWC, VA-CCN Collaborate to Expand Access to SPRAVATO(R) Treatments”
Delic Holdings (CSE: DELC) (OTCQB: DELCF) (FRA: 6X0), a leader in new medicines and treatments for a modern world, announced that CEO Matt Stang will be participating in the 24th annual H.C. Wainwright Annual Global Investment Conference. The three-day event is scheduled for Sept. 12–14, 2022. During his presentation, Stang will provide a summary of … Continue reading “NetworkNewsBreaks – Delic Holdings Corp. (CSE: DELC) (OTCQB: DELCF) (FRA: 6X0) CEO to Present at H.C. Wainwright Annual Global Investment Conference”
Delic Holdings (CSE: DELC) (OTCQB: DELCF) (FRA: 6X0) CEO Matt Stang was included in World Biz magazine’s Top-100 CEOs in Innovation for 2022. The announcement noted that Stang was recognized as a champion of creativity who is dedicated to making a positive environmental and social impact. Stand cofounded Delic Corp., which has grown into a … Continue reading “NetworkNewsBreaks – Delic Holdings Corp. (CSE: DELC) (OTCQB: DELCF) (FRA: 6X0) CEO Makes Top-100 Innovation List, Company Postpones Meet Delic Event”
Silo Pharma (OTCQB: SILO) recently reported that the University of California San Francisco (“UCSF”) had successfully administered psilocybin to a test group of Parkinson’s disease patients. The psilocybin was administered “as part of a scientific research agreement (‘SRA’) entered with Silo in June 2021 to ‘determine the effects of psilocybin on inflammatory markers of patients … Continue reading “NetworkNewsBreaks – Silo Pharma Inc. (SILO) Fusing Traditional Therapeutics with Psychedelic Research”
